Literature DB >> 24635871

Stereotactic body radiotherapy in the treatment of pancreatic cancer.

Nicholas Trakul1, Albert C Koong2, Daniel T Chang3.   

Abstract

Most patients diagnosed with pancreatic cancer are unable to have a curative surgical resection. Chemoradiation is a standard of care treatment for patients with locally advanced unresectable disease, but local failure rates are high with conventionally fractionated radiotherapy. However, stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy offers an alternative type of radiation therapy, which allows for the delivery of high-dose, conformal radiation. The high doses and shorter overall treatment time with SBRT may provide advantages in local control, disease outcomes, quality of life, and cost-effectiveness, and further investigation is currently underway. Here, we review the technology behind SBRT for pancreatic malignancy and its future direction in the overall management of pancreatic cancer.
© 2013 Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24635871     DOI: 10.1016/j.semradonc.2013.11.008

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  26 in total

Review 1.  Neoadjuvant radiotherapeutic strategies in pancreatic cancer.

Authors:  Falk Roeder
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 2.  Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics.

Authors:  Joseph Yoo; C Andrew Kistler; Linda Yan; Andrew Dargan; Ali A Siddiqui
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 3.  Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Authors:  Samuel K Kim; Cheng-Chia Wu; David P Horowitz
Journal:  J Gastrointest Oncol       Date:  2016-06

Review 4.  Optimizing tumor immune response through combination of radiation and immunotherapy.

Authors:  Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan
Journal:  Med Oncol       Date:  2017-08-21       Impact factor: 3.064

5.  Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.

Authors:  E Gkika; S Adebahr; S Kirste; T Schimek-Jasch; R Wiehle; R Claus; U Wittel; U Nestle; D Baltas; A L Grosu; T B Brunner
Journal:  Strahlenther Onkol       Date:  2017-01-30       Impact factor: 3.621

Review 6.  Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians.

Authors:  Rosella Spadi; Federica Brusa; Agostino Ponzetti; Isabella Chiappino; Nadia Birocco; Libero Ciuffreda; Maria Antonietta Satolli
Journal:  World J Clin Oncol       Date:  2016-02-10

7.  Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.

Authors:  Robert de W Marsh; Mark S Talamonti; Marshall S Baker; Mitchell Posner; Kevin Roggin; Jeffrey Matthews; Daniel Catenacci; Mark Kozloff; Blase Polite; Michele Britto; Chi Wang; Hedy Kindler
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

8.  An evaluation of motion mitigation techniques for pancreatic SBRT.

Authors:  Warren G Campbell; Bernard L Jones; Tracey Schefter; Karyn A Goodman; Moyed Miften
Journal:  Radiother Oncol       Date:  2017-05-29       Impact factor: 6.280

Review 9.  A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer.

Authors:  Chenwi Ambe; William Fulp; Gregory Springett; Sarah Hoffe; Amit Mahipal
Journal:  J Gastrointest Cancer       Date:  2015-09

10.  Dosimetric effect of the intestinal gas of online adaptive stereotactic body radiotherapy on target and critical organs without online electron density correction for pancreatic cancer.

Authors:  Chen Su; Hiroyuki Okamoto; Shie Nishioka; Tatsuya Sakasai; Daisuke Fujiyama; Yuki Miura; Yuki Tsunoda; Junichi Kuwahara; Satoshi Nakamura; Kotaro Iijima; Takahito Chiba; Keita Kaga; Mihiro Takemori; Hiroki Nakayama; Shouichi Katsuta; Koji Inaba; Hiroshi Igaki; Yuko Nakayama; Jun Itami
Journal:  Br J Radiol       Date:  2021-02-05       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.